BioNxt Solutions – Attack on new highs

On track for an all-time high

Even the emotional post by the energetic US president could not halt the positive development of BioNxt shares. With a closing price of CAD 0.91 on Friday, up 4.6%, the share price is heading towards its all-time high of CAD 1.10. After a correction in mid-September, the share price was able to hold its striking support zone at CAD 0.60 and began a counter-movement amid rising volume. The technical indicators suggest this could be just the beginning. The MACD trend follower generated a buy signal near the zero line last week, while the RSI stands at a moderate 55.74 points and is still far from the overbought range.

Given the fundamental achievements in recent weeks, this level should certainly serve as an initial interim target, especially given the Company's enormous potential at a market value of CAD 103.20 million.

Attack with MS drug – Fast-track procedure for US patent underway

In addition to the completed uplisting to the US OTCQB segment and a targeted investor relations offensive, BioNxt shares came into the focus of investors with a milestone announcement. The German-Canadian innovator announced that it had filed a "fast-track" patent application under the so-called Track One program with the US Patent Office for its novel sublingual administration of Cladribine for the treatment of multiple sclerosis (MS). The special feature of this process is the promise of an accelerated review, with a decision expected within the next 9 to 12 months.

The patented technology is based on an oral thin film that dissolves under the tongue. Cladribine is a proven active ingredient for the treatment of MS. However, in this innovative dosage form, it is expected to act faster, enable better absorption in the body, and, above all, improve treatment compliance. This is particularly relevant for patient groups with swallowing difficulties or those who wish to avoid invasive treatments.

The application also covers other autoimmune diseases, including myasthenia gravis and lupus nephritis, thus opening up a wide range of applications for the platform technology. Parallel to the US patent application, BioNxt has initiated the patent process in other key regions such as the EU, Canada, Japan, and Australia. Feedback from Europe and Eurasia has already been positive, with the novelty and applicability of the technology being recognized.

The strategic timing of the application is no coincidence. The final bioequivalence studies and potential partnerships with pharmaceutical companies are imminent. Securing patent protection in good time increases the Company's value and strengthens its negotiating position.

Backed by the MS market and ambitions as a takeover candidate

The multiple sclerosis (MS) market is among the fastest-growing segments in the pharmaceutical industry: in 2024, global sales of MS drugs amounted to around USD 21.1 billion, and forecasts predict that this will almost double to around USD 39 billion by 2032. There is a clear trend toward growing demand for effective, tolerable, and convenient therapies, with nearly half of the revenue coming from the US market alone.

BioNxt Solutions has strategically positioned itself in this high-growth environment. With its platform technology for sublingual thin films and patches that absorb drugs directly through the mucous membrane or skin, the Company addresses precisely those weak points of traditional dosage forms. Greater comfort, improved bioavailability, and reduced side effects are the key advantages.

The sublingual administration of cladribine as BNT23001 in the future, for example, opens up a concrete opportunity for market entry in a rapidly growing MS segment, especially at a time when established biologics like Roche's Ocrevus face patent expirations. If BioNxt achieves regulatory approval or at least clinically robust data, the Company would be in the spotlight of large pharmaceutical companies that urgently need new product offensives.

However, management's ambitions go even further. BioNxt plans to extend its platform technology to other active ingredients, particularly in the areas of obesity, neuroimmune diseases, and oncology. This increases the potential from a single product to a globally scalable platform.

The current valuation does not yet reflect the strategic value of the technology. If the Company overcomes clinical hurdles, an exit via licensing or direct acquisition by a pharmaceutical or biotech company is entirely plausible. For risk-tolerant investors with an eye on health-tech trends, BioNxt represents one of the most compelling opportunities in the biotech sector today.